This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca Plc (NYSE: AZN ) received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer therapy Truqap gaining approval for a subset of prostate cancer patients and its kidney disease treatment Ultomiris receiving Priority Review for a new indication. Truqap Becomes First Targeted Option For PTEN-Deficient Prostate Cancer On Friday, the FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously known as metastatic hormone-sensitive prostate cancer . The approval makes the regimen the first and only targeted treatment available for this patient population when identified through an FDA-authorized test. data-variant="card" data-news-mode="manual" > Read Also: AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials The ... Full story available on Benzinga.com